On July 30, the US Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.
For more information read the FDA announcement and the Johnson & Johnson announcement.
Posted 7/31/2024
Recognizing the critical role advanced practice providers and allied health professionals play in the care continuum, the American Oncology Network provides infrastructure, leadership, and professional growth opportunities to empower these members of the cancer care team to practice at the top of their license.
